AstraZeneca’s Dual-Antibody Injection Cuts Risk of COVID-19 Infection

AstraZeneca’s one-time dual-antibody injection cut the risk of symptomatic COVID-19 by up to 83 percent and the risk of severe disease by 88 percent in two studies of high-risk patients.
Source: Drug Industry Daily